13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001643354
Total reported value
$20.9M
$20.9M
19 檔
30.6%
According to the latest 13F quarterly dataset, Lion Point Capital, LP managed an equity portfolio of $20.9M at the end of Q2 2025, spanning 19 distinct U.S. exchange-listed positions.
In Q2 2025, Lion Point Capital, LP adopted a defensive or profit-taking posture, trimming 1 positions and completely liquidating 3 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | FENC | Fennec Pharmaceuticals Inc | Stock-Other | 11.03% | +1.65% | — | |
| 2 | ARDX | Ardelyx Inc | Stock-Other | 8.93% | -1.47% | — | |
| 3 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 8.62% | — | — | |
| 4 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 7.62% | -0.44% | — | |
| 5 | INSM | Insmed Inc | Stock-Healthcare | 7.28% | — | -65.08% | |
| 6 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 7.26% | -0.34% | — | |
| 7 | MIST | Milestone Pharmaceuticals In | Stock-Other | 7.23% | -0.57% | — | |
| 8 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 5.93% | — | — | |
| 9 | JSPR | Jasper Therapeutics Inc | Stock-Other | 5.52% | -1.50% | — | |
| 10 | BNTC | Benitec Biopharma Inc | Stock-Other | 4.93% | +0.02% | — | |
| 11 | GERN | Geron CORP | Stock-Other | 4.79% | -1.61% | — | |
| 12 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 4.41% | -0.08% | — | |
| 13 | IRON | Disc Medicine Inc | Stock-Other | 3.81% | -0.27% | — | |
| 14 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 3.50% | -1.27% | — | |
| 15 | RGNX | Regenxbio Inc | Stock-Other | 3.22% | +0.19% | — | |
| 16 | BHVN | Biohaven Ltd. | Stock-Other | 2.17% | +1.07% | — | |
| 17 | ✓ | Mersana Therapeutics Inc | Stock-Other | 1.29% | — | — | |
| 18 | MCRB | Seres Therapeutics Inc | Stock-Other | 1.29% | -0.48% | — | |
| 19 | HUMA | Humacyte Inc | Stock-Other | 1.18% | +0.07% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MIST | Milestone Pharmaceuticals In | +4.4% | — | Unchanged |
| 2 | FENC | Fennec Pharmaceuticals Inc | +3.4% | — | Unchanged |
| 3 | KNSA | Kiniksa Pharmaceuticals International, plc | +2.1% | — | Unchanged |
| 4 | BBIO | Bridgebio Pharma Inc | +1.9% | — | Unchanged |
| 5 | JSPR | Jasper Therapeutics Inc | +1.5% | — | Unchanged |
| 6 | MCRB | Seres Therapeutics Inc | +1.3% | NEW | New buy |
| 7 | ✓ | Avadel Pharmaceuticals PLC ADR | +1% | — | Unchanged |
| 8 | RGNX | Regenxbio Inc | +0.6% | — | Unchanged |
| 9 | IRON | Disc Medicine Inc | +0.5% | — | Unchanged |
| 10 | HUMA | Humacyte Inc | +0.3% | — | Unchanged |
| 11 | ✓ | Mersana Therapeutics Inc | -0.1% | — | Unchanged |
| 12 | SPRU | Spruce Power Holding Corporation | -0.1% | EXIT | Sold out |
| 13 | ARQT | Arcutis Biotherapeutics Inc | -0.2% | — | Unchanged |
| 14 | BNTC | Benitec Biopharma Inc | -0.2% | — | Unchanged |
| 15 | GERN | Geron CORP | -0.3% | — | Unchanged |
| 16 | MLYS | Mineralys Therapeutics Inc | -0.7% | — | Unchanged |
| 17 | SNDX | Syndax Pharmaceuticals Inc | -0.8% | — | Unchanged |
| 18 | BHVN | Biohaven Ltd. | -1.3% | — | Unchanged |
| 19 | MCRB1EUR | Seres Therapeutics Inc | -1.5% | EXIT | Sold out |
| 20 | ARDX | Ardelyx Inc | -1.6% | — | Unchanged |
| 21 | BLE0 | Bluebird Bio Inc | -2.5% | EXIT | Sold out |
| 22 | INSM | Insmed Inc | -7.6% | -65.08% | Trim |
According to official SEC Form 13F filings, Lion Point Capital, LP reported a total U.S. public equity portfolio value of $20.9M across 19 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including FENC, ARDX, KNSA) accounted for 30.6% of total reported equity market value during Q2 2025.
Top New Position Initiated
MCRB
市值: $189.3K
Top Position Liquidated / Trimmed
BLE0
前期市值: $385.1K
During Q2 2025, Lion Point Capital, LP's top holdings by market value included FENC (11.0%)、ARDX (8.9%)、KNSA (8.6%). The largest single position, FENC, represented 11.0% of total portfolio value.
In Q2 2025, Lion Point Capital, LP made 5 total portfolio adjustments, initiating 1 new buys, adding to 0 positions, trimming 1 holdings, and fully liquidating 3 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.